glp-1/gip + b12 Limited time GLP-1 weight loss

Obesity is a complex disease that requires comprehensive, lifelong care

Neurotoxicology 92:166179

Minireview: Finding the Sweet Spot: Peripheral versus Central Glucagon-like Peptide 1 Action in Feeding and Glucose Homeostasis

In addition, we are developing similar tools for the GIP receptor. Dual agonists for the incretin hormone GLP-1 and the GCG receptor are emerging as a potential new class of therapeutics for Type 2 Diabetes, a disease affecting over 400 million people worldwide (WHO 2019)

6 Alternatively, some patients may be prescribed sulfonylureas or thiazolidiniones to improve insulin secretion, but both of these treatment options are associated with an elevated risk of heart failure making them unsuitable for use in patients with cardiovascular disease